Biogen Inc. (BIIB) Earnings Call Transcript & Summary

July 29, 2026

NASDAQ US Health Care Biotechnology earnings 69 min

What were the key takeaways from Biogen Inc.'s July 29, 2026 earnings call?

In Biogen's Q2 2026 earnings call, the company reported total revenue of $2.7 billion, up 3% year-over-year, driven by strong performance in its growth portfolio, which generated over $1 billion in revenue, reflecting a 24% increase year-over-year. The company also announced a positive shift in guidance, now expecting a mid-single-digit percentage increase in total revenue for the year, up from a previous decrease. Non-GAAP diluted EPS guidance for 2026 was updated to a range of $12 to $13, reflecting the impact of the recent acquisition of Apellis Pharmaceuticals.

What topics did Biogen Inc. cover?

  • Growth Product Portfolio Expansion: Biogen's growth portfolio generated over $1 billion in revenue, up 24% year-over-year, surpassing the legacy MS portfolio. Management stated, "this performance was driven by our growth portfolio," indicating a successful transition in their product strategy.
  • Acquisition of Apellis Pharmaceuticals: The integration of Apellis is progressing well, with SYFOVRI and EMPAVELI contributing a combined $128 million in revenue since the acquisition date. Management noted, "the Apellis acquisition accelerates our return to growth," highlighting its strategic importance.
  • LEQEMBI IQLIK Approval: The FDA approved LEQEMBI IQLIK initiation, which is expected to enhance patient access and market penetration. Management expressed confidence, stating, "we believe that IQLIK will evolve this market," indicating its potential impact on future revenue.
  • Pipeline Development and Upcoming Trials: Biogen is entering a multiyear registrational cycle with five upcoming Phase III readouts across key indications. Management emphasized, "we are now entering a multiyear registrational cycle," which could significantly shape future growth.
  • Guidance Update: Biogen raised its revenue guidance for 2026 from a mid-single-digit percentage decrease to an increase, reflecting strong performance expectations. CFO Robin Kramer stated, "we are pleased to be increasing our total revenue guidance," indicating management's confidence in growth.

What were Biogen Inc.'s July 29, 2026 results?

  • Total Revenue: $2.7 billion (+3% YoY)
  • Core Pharmaceutical Revenue: $1.8 billion (+4% YoY)
  • Non-GAAP Diluted EPS Guidance: $12 to $13

Biogen's strong Q2 results and positive guidance updates signal a potential turnaround in its growth trajectory, driven by successful product launches and strategic acquisitions. Investors should monitor the upcoming trial data and integration progress of Apellis as key catalysts, while also keeping an eye on VUMERITY's performance and competitive pressures in the market.

Earnings Call Speaker Segments

Tim Power

executive
#1

Appreciate that, Jess, and greetings to everybody this morning. It's a pleasure to have you join us for Biogen's earnings discussion covering the second quarter of 2026. Statements we make today looking ahead will carry risks and uncertainties, and those could lead to actual outcomes differing in a material way from what we project. A full list of risk factors appears in our SEC filings, and we urge you to take a look at those. You can find our earnings release along with other materials about our results, plus the reconciliations comparing GAAP and non-GAAP figures we discuss today, in the Investors area of biogen.com. Slides for this call have additionally been placed on a website for use during our remarks. Joining me today are Chris Viehbacher, our President and Chief Executive Officer; Dr. Priya Singhal, who leads Development; and our Chief Financial Officer, Robin Kramer; Alicia Alaimo, President of North America, will additionally be on hand for the Q&A portion. After some opening remarks, we'll transition to Q&A, and so that we can address as many questions as possible, we ask that each of you please ask only one question. I'll hand things over now to Chris.

Chris Viehbacher

executive
#2

<<inaudible>> aiming for revenue growth that can be sustained over time. So, if I break down the three things I believe feed into that: first, our portfolio of growth products; even prior to factoring in the items from Palace, we've already recorded substantial growth; in fact, our growth portfolio has now surpassed our legacy MS portfolio. And most recently, two key accomplishments have strengthened that. The first is high-dose SPINRAZA, which we've observed across every market. Japan was the initial market to grant approval, followed by Europe, and now the U.S., and we're beginning to see this expand into additional international markets. In each of those markets, this conversion has moved far more quickly than we had anticipated. So this marks a major milestone for us. It's an incredibly tough market out there, and what really matters is how well a treatment works. With the high dose of SPINRAZA, we've seen real improvements in efficacy. We look at this franchise as something for the long haul, since salinersen is coming along behind it — so we're focused on protecting our share. In fact, we're picking up on a few anecdotal switchbacks, particularly patients moving from the oral product to SPINRAZA. That's important not only for this quarter but for where the franchise stands over time. The other major win this quarter was basically the launch of LEQEMBI IQLIK — it's the first Alzheimer's therapy of its kind. So we're now providing a single dosing approach for both initiation and maintenance. I'd say there are probably two opportunities in particular here, perhaps even three. The first is clearly that, with the biweekly infusion, quite a few physicians are weighing carefully which patients will actually qualify for treatment. If they doubt the patient can arrive on their own, or there isn't a caregiver willing to devote the time to bring that patient to the infusion centers; those patients frequently aren't offered treatment. So this ought to perhaps make it simpler for a wider segment of patients to qualify for treatment. Another thing we see as a possible positive is leaving patients on treatment for a longer period. And finally, we feel there's an edge over the competition, since whatever benefit the rival product had from being dosed just once a month now looks much less significant once a subcutaneous option that can be given at home is on the table for them. The next element of that durable growth comes from our pipeline, which we'll turn to and talk about shortly. Then the third element is genuinely CYFOVRI along with Pavel from the appellate acquisition. For those two products combined, you've seen strong growth in the double digits, both for the entire quarter and on a year-to-date basis. So revenue consolidation only began on May 14, the day we finalized the deal, yet these products are already contributing meaningfully to our growth. Let me pause for a second and note that, looking back at all the integrations I've seen over my career, one truly essential measure is how sales perform through that messy period within an organization. Huge deals carry an enormous amount of ambiguity. And in my opinion, sustaining revenue levels stands out as the most vital indicator of a successful integration. That's what I think we've seen so far, and the biggest factor is that this transaction is mostly a U.S. First, full credit goes to Alicia—her leadership, her group, and the effort they made reaching out so the Appellate team feels positive about becoming part of Biogen. Beyond that, whenever I talk with individuals who came from Apellis and now work at Biogen, the impression I get is one of energy, passion, and dedication. So this acquisition's importance leaves us feeling very encouraged. Turning to the next slide—Priya will cover this in greater depth—we have a foundation that continues to expand, and we currently have 5 registrational Phase III clinical trial results coming. To break it down: there are 2 in SLE for lupus, 1 in CLE for lupus, 1 for AMR, and 1 that's essentially from our partner Stoke in Dravet syndrome. So every one of those is now expected within the coming 4 quarters. That makes them near-term events that could truly reshape Biogen's longer-term growth trajectory. As we've mentioned previously, we're also in the process of rebuilding our early-stage pipeline. For 3 years, we essentially didn't file a single IND. We took some pretty bold steps to restructure our research organization and the way we conduct research; and what's encouraging is that I believe we're already in a far stronger position with our early-stage pipeline. Part of that is coming in sooner than anticipated. We've already had 3 INDs this year. There's still plenty ahead of us. We've already completed several important partnerships — for instance, the one with Bank and Dave in the prior year — and bringing Bayer on board this year gives our early-stage pipeline a significant lift as well. The way to think about it is that the money going out the door now is aimed at the offerings that will hit the market around the middle of the next decade. Even so, you have to get moving right away if you're hoping to capture that expansion later on. Now, turning to this slide — we originally put it up at JPMorgan back near the start of this year. During that call, your point was that several things could fuel growth in the near term, and you pointed to LEQEMBI IQLIK, VUMERITY, SPINRAZA, SKYCLARYS and Casady; that collection of products has now surpassed our older MS lineup and posted strong expansion this quarter. Once Ciporin and Pavel are factored in, those offerings on their own are sufficient to put Biogen back on a growth trajectory; and regarding what lies ahead, we've just covered those upcoming data readouts, which form the second wave, the late-stage registrational pipeline. Each of these products carries considerable promise. And for Biogen, this amounts to a rather significant transformation as well. When I joined 3.5 years ago, the neurologist was essentially the only specialist we called on. In MS, we still had a handful of products we could promote, plus we had SPINRAZA. Today, we're calling on rheumatologists, dermatologists, and nephrologists outside the U.S; also epileptologists and nephrology transplant. So the breadth of our portfolio has expanded considerably; that's thrilling, yet it also means we're now moving beyond simply expanding the foundation of growth to actually delivering on that growth story. So a lot is happening within the company to ensure each of those launches succeeds. At the same time, we're watching the longer term, and that's the third wave, the possibilities for growth further out. Thanks, Nursing. You've reviewed those figures, and it's an exciting new approach for Alzheimer's, though it isn't really central to the equity narrative right now. Still, looking further out, it might contribute substantially to Biogen's expansion; this is precisely why that early stage pipeline I referenced earlier—the one that was taken out—carries such weight in the research portfolio. As for BD M&A, I think we have the capabilities required to deliver near term growth. Our approach to M&A will likely be less deliberate and more opportunistic, but when it comes to earlier stage development, we will certainly be deliberate.

Chris Viehbacher

executive
#3

Ideally, what we want is to bring in assets somewhere between the development candidate stage and IND. So if you ask what the opportunity looks like — and keep in mind these aren't revenue forecasts, just an early read on the addressable market coming out of the pipeline — I'd say work is still ongoing. Lupus, for instance, represents a potential $8 billion market for us. MS is a market of more than $20 billion, and honestly we aren't at a point yet where we can really spell out how we'd capture that. Today it's probably a $2 billion to $3 billion market, yet there's no genuine reason this market couldn't reach the size of MS. Even putting that aside and taking just the $8 billion figure, that's a meaningful opportunity for us to pursue. And clearly, that's not only with SLE — we'd also hope to be first to gain approval for CLE. Then there's AMR, with roughly 11,000 patients in the U.S. by itself. Phase III data arrives in early 2027, and that's an addressable market of at least $2 billion; it hinges on the pricing you apply, but given the pricing now emerging in IgAN, a spillover effect onto AMR is going to happen. Then, if you consider microvascular inflammation, another indication we're going after, that market could expand too. And naturally, later on we have IgAN and PMM data coming for felzartamab. After that, Dravet syndrome. As you're aware, we hold the ex U.S. rights, yet even across ex U.S. markets there are roughly 7,000 patients in Europe by itself; adding up all our key Biogen territories, that's an opportunity of at least $2 billion. Again, we're hard at work on that. In some respects, we're still 18 to 24 months away from launch on those items and we keep working. But this demonstrates the potential; it also demonstrates why execution with excellence matters, and we're investing today to ensure those launches succeed; so let's move to the last slide. If you looked at Biogen before the Appellate announcement, the investor consensus was that Biogen would be roughly flat through 2030. I believe we're already watching that consensus begin to shift, since people are starting to appreciate the Apellis transaction. But the way we certainly see it, when you take the appellate marketed products and add them to our own growth product portfolio, I think we're looking at a growing picture. And when you then layer in the late-stage registration pipeline — I can recall vividly one investor in a meeting we held right after announcing Appellate saying, "I get it. The late-stage pipeline now comes on top of a growing basis instead of a stable basis." And I think this slide neatly captures the strategy for returning to sustainable revenue growth. So with that said, I'll hand things over to Priya, who's able to share a bit more detail on that late-stage registration pipeline.

Priya Singhal

executive
#4

Thank you, Chris, and good morning to all of you. As we bring the new Biogen to life, a significant portion of our transformation and our near-term chance to grow stems from our late-stage pipeline, just as Chris said, and this future has me energized. The reason is that right now, we hold one of the most robust and varied late-stage pipelines ever seen at Biogen, with numerous near-term chances to generate value over the coming years. We showed this slide to you back at the start of the year. And now, you can see that we are making good on the opportunities we set out, among them the FDA approval of IQLIK initiation, a meaningful innovation for patients and caregivers. In addition to IQLIK, Biogen and Eisai shared new data at AAIC earlier this month; this encompassed real-world evidence backing the long-term benefits of continuous LEQEMBI treatment. We also presented new data for David Nelson, establishing proof of concept in Alzheimer's disease, and our focus now is on developing the next steps for the program. And on a broader level, we keep demonstrating medical leadership throughout our portfolio, with significant new data presentations for both tisotumab and ZorivoNursen. Although these milestones strengthen the potential of our portfolio as it stands, what makes this stretch especially thrilling is what is coming soon; we are now starting a multiyear registrational cycle, kicking off with SLE data before this year ends; and then multiple catalysts running through the rest of the decade. And even as we stay focused on pushing forward our high conviction late-stage opportunities, at the same time, we keep investing in the next wave of innovation. The progress achieved this quarter has considerably sped up the transformation of our pre-proof-of-concept pipeline. At this stage in the year, we have also moved past our high-risk, high-reward readouts, as we noted at the outset. This covers our Phase II BTK inhibitor, BIB91, where we reached proof of concept in relapsing remitting MS. And consistent with our disciplined approach to how we advance assets, we are assessing next steps, in light of how increasingly competitive that market has become. As we rebuild our early-stage pipeline, we anticipate adding 6 new programs this year, among them new Phase II proof-of-concept studies to broaden the potential of <<inaudible>> and <<inaudible>> in autoimmune disease, along with first-in-human studies from our internal pipeline and the lead asset from the pending Vatera acquisition, which is already in Phase 1 now. All told, we believe these investments are constructing a durable innovation engine with the promise of delivering sustainable, long-term growth and value creation. So as we step back and survey the next several quarters, we anticipate readouts from 5 registrational studies across 4 important indications, SLE, CLE, AMR and Dravet syndrome. And given the strong execution of our teams and enrollment momentum, we have also sped up the expected Phase III readouts for vazadimab in AMR and mitipiimab in CLE, with data now expected in the first half of 2027. Also coming up later in the fall, we're eager to share fresh 52-week results from the Phase II part of the Ametis trial, which is still underway, when we present at the EADV Annual Conference. Our belief is that this will deliver meaningful understanding regarding how long litefolumab's response lasts in CLE. When you put these milestones together, they should yield significant data across the coming months, and that could help determine the shape of our next stage of growth. To wrap up, the choices we've made strategically and the money we've invested across the last 3 to 4 years have put us in a position to produce near-term readouts while also pushing forward long-term innovation. We're excited to keep updating you on how things are going; so with that, I'd like to hand the call over now to Robin, who is going to walk through the financial update for the quarter. Thanks.

Robin Kramer

executive
#5

Thank you, Priya. Good morning to all of you. It's a pleasure to be here with everyone today after a robust top-line showing in the second quarter. Core pharmaceutical revenue for Q2 totaled $1.8 billion, representing a 4% increase versus the same period a year ago and a 12% rise sequentially. Our growth portfolio powered this result, delivering more than $1 billion in revenue during the quarter — a 24% gain year-over-year and 25% quarter-over-quarter. The Biogen stand-alone growth products, leaving out our appellate SYFOVRI and Apave revenue, came in at $933 million, which is up 9% compared with a year earlier and 10% versus the prior quarter, and as Chris pointed out, this again exceeded the revenue from our legacy MS portfolio this quarter. Adding SYFOVRI and EmpaVelli through the Appellate transaction has made our growth portfolio even stronger; together they brought in $128 million for the period after the May 14 acquisition date. The results this quarter reflect solid commercial execution and the meaningful strides we've taken in transitioning our portfolio. I'd like to now walk you through several key highlights from our core pharmaceutical product performance during the second quarter. Let's begin with the growth portfolio. Sales for SPINRAZA came in at $402 million, which works out to a 2% gain versus the same period last year and 7% higher than the prior quarter. What pushed this forward was demand plus inventory building for the high-dose regimen here in the U.S., though that was partially counterbalanced by the timing of shipments in some markets beyond the U.S. The high-dose version of SPINRAZA received approval in the U.S. back in March, in the EU during January, and in Japan in the previous year. As patients make the switch to the high-dose regimen, we bring in revenue from the one-time transition dose. The maintenance version of high-dose SPINRAZA is priced at parity with SPINRAZA; we're pleased that the shift toward high dose has gone smoothly and that excitement among patients and prescribers for an option with higher efficacy has been strong. Additionally, we view the prospects for Salanersen — our registrational pipeline candidate that just received Breakthrough Therapy designation — as promising. VUMERITY brought in $197 million, a 7% drop compared with the same quarter last year, partly because of inventory timing, though it rose 10% versus the prior quarter. For the opening six months of 2026, revenue was up 7% relative to the equivalent stretch of last year. LEQEMBI's end-market sales reached $184 million, climbing 15% year-over-year and 9% quarter-over-quarter. Growth across major markets including the U.S., Japan and China carried on. And, as Priya mentioned, we're glad that earlier this month the FDA cleared IQLIK for initiation. SKYCLARYS saw rising patient demand both inside the U.S. and beyond it. In Q2, we brought in $168 million in revenue, which represents a 29% increase compared to the same period last year and an 11% rise from the prior quarter. SKYCLARYS Claris is now on the market in 36 countries, and our expectation remains that most of SKYCLARYS's expansion will come from outside the U.S. as we continue rolling out the launch. ZURZUVAE continued to demonstrate robust growth in underlying demand, generating $71 million in revenue, and we're happy to share that ZURZUVAE is now available in Germany as well. Turning to our MS portfolio, I'd like to highlight that TYSABRI maintained steady demand despite a biosimilar launching in both the U.S. and Europe. Revenue for the second quarter came to $451 million, a decline of 1% versus the prior year and a rise of 2% compared with the previous quarter. We invested over many years to make Tysabri a key option for patients with MS, and it's gratifying to see that reflected in how resilient Tysabri has been so far. Now shifting to news about the Appellate acquisition, which completed in the middle of the quarter on May 14. Integration is going smoothly, and both SYFOVRE and EMPAVELI delivered strong results during the quarter. SYFOVRE maintained its market leadership, with total revenue for the quarter reaching $162 million, up 8% both year-over-year and quarter-over-quarter, while total commercial injections rose 13% year-over-year. EMPAVELI continues its rollout for C3G and primary IC-MPGN, with revenue reaching $46 million — up 123% versus a year ago and 12% higher than the prior quarter. Through the Apellis acquisition, we accelerate our path back to growth. Two best-in-class medicines already on the market join our growth portfolio, and we expect them to add substantially to top line growth both near term and long term. Taken together, SYFOVRE and EMPAVELI should expand at a mid- to high-teens rate at minimum through 2028. Looking further out, we anticipate this deal will substantially lift our non-GAAP diluted EPS CAGR through the close of this decade. On the other income expense line, we're looking at an impact of about $120 million to $130 million in 2026 and again in 2027, driven by IT expense and interest income we won't receive because of how the transaction is financed. By the close of 2027, we expect run rate synergies of no less than $250 million, primarily achieved by streamlining general and administrative costs and research and development. For 2026, non-GAAP EPS dilution should come in around $0.85, largely because of financing costs associated with the transaction. Come 2027, we expect the transaction to add to non-GAAP diluted EPS. We think this deal puts our capital to good use and will boost both our revenue and earnings growth potential, plus the therapeutic areas that fit with our immunology and rare disease approach. Now for the financial highlights: for the quarter, total revenue came in at $2.7 billion, which is 3% higher than the same period last year. The anti-CD20 royalties and profit share that sit within other revenue brought in $514 million, a 10% increase compared with a year ago. That improvement came from OCREVUS royalties, helped by the recent subcutaneous launch, along with Rituxan holding up well in the U.S. In addition to the revenue that SYFOVRE and EMPAVELI contributed during the quarter, which we covered earlier, the results of operations we are reporting for the second quarter of 2026 reflect 0.5 quarter of the operating expenses and financing costs tied to the Appellate acquisition. Looking at non-GAAP cost of sales measured as a percentage of revenue, the figure stood at 22% for Q2 2026, compared with 21% in the prior year. That rise stemmed mainly from product mix, driven in large part by higher contract manufacturing revenue. On a GAAP basis, cost of sales relative to revenue also suffered. The reason was bigger amortization charges connected to the fair value step-up on inventory from the Reata transaction for SKYCLARYS, along with the Appellate transaction for SYFOVRE and EMPAVELI. Now on the non-GAAP core OpEx line — that's R&D plus SG&A — we saw a 20% increase from the same period a year ago. What's driving that is about $95 million of Appellate operating expenses that got recorded starting on the May 14 acquisition date all the way through the end of the quarter. And on the R&D front, you're also seeing what we're putting into Phase III clinical programs — felzartamab for the MDI indication and <<inaudible>>, with both of those advancing as registrational studies in the back half of 2025; plus lidafilimab, where Phase III SLE data is expected later this year, along with a $25 million decline in R&D funding year over year that comes from the royalty pharma funding for lidafilimab. When you look at sales and marketing, that uptick reflects the support behind our U.S. and international product launches, plus prelaunch investments in our late-stage high conviction pipeline.

Robin Kramer

executive
#6

Like we said before, in the second quarter of 2026 we booked $164 million in acquired IPR&D and milestone charges tied to what we've put into the development pipeline. That figure includes a $100 million upfront payment to TJ Bio, which relates to buying the felzartamab rights in China and hands us rights to felzartamab globally. It also includes a $45 million milestone payment to Ionis tied to kicking off the Phase III trial for salinersen and SMA, plus a $15 million upfront payment to Ionis so we could opt into BIB147 in broad ALS. Now let's move on to cash flow and the balance sheet. We keep producing robust cash flow, with roughly $408 million of free cash flow coming in during the second quarter. When the quarter ended, we had $1.3 billion of cash along with $6.8 billion of net debt. The Appellate transaction closed during the second quarter, and it was funded by drawing $3.6 billion of cash off the balance sheet plus $2 billion of term loans. In Q2 we paid back $200 million of the term loan, and we still anticipate paying off what remains of those term loans before 2027 ends. Let's shift to guidance. Given how we expect revenue to perform in our base business, which covers our growth products and Tysabri, the update to our guidance shows a $0.60 bump in the underlying business guidance versus what we previously guided. We're happy to be raising total revenue guidance from a mid-single-digit percentage decline to a mid-single-digit percentage gain. That captures both the performance we expect from our growth products into cabin and the fact that SYFOVRE and EMPAVELI are now part of our product portfolio. Our guidance additionally captures updates to core operating expenses, other income and expense, and our full year tax rate, mostly so we can fold in the effect of acquiring Apellis. For the back half of 2026, we anticipate core operating expenses landing between $2.65 billion and $2.7 billion. Our guidance also captures updates related to our strategic investments in the early and late-stage pipeline, along with those tied to our near and midterm growth. It takes into account transactions already completed and our present expectations for those still to come over the rest of the year. It takes into account an impact of roughly $3 on non-GAAP diluted EPS from charges tied to IPR&D and milestones, which includes the Q2 TJ Bio transaction, the Ionis milestone for getting the first patient dosed in STELLAR 1, our pivotal Phase III selinersen study in SMA, and the pending Vatera transaction that adds a Phase 1 immunology asset to the early-stage pipeline and should close in Q3, plus the anticipated full year 2026 $0.85 dilution from the Appellate transaction, again mostly because of financing costs. Our revised 2026 full year non-GAAP diluted EPS range now sits between $12 and $13. Kindly take a look at this slide, along with Slide 25 in the appendix to this presentation and our press release, for additional key assumptions underlying full year 2026 guidance. To wrap up, robust commercial execution across the Biogen-based business, together with the addition of SYFOVRE and EMPAVELI, delivered a strong top line in Q2, while finishing the Apellis acquisition speeds up our top line and bottom line growth potential in both the near and midterm. With that, I'll hand the call back to Tim so we can open it up for questions.

Tim Power

executive
#7

Thanks, Robin. Jess, could we go to our first question, please? .

Chris Schott

analyst
#8

Thanks. Sorry, I'm back on mute. I've got one quick thing about HD SPINRAZA. Could you go into a bit more detail regarding how the ramp-up is tracking versus what you expected internally? And are there any metrics you can give us about the conversion happening in markets where the product has been available longer? As part of that, maybe you could also address how big an effect patients switching back to HD has on total volumes — and on the product itself? I'm basically just after a general picture of how this is going and what it's doing to the franchise.

Alisha Alaimo

executive
#9

Chris, it's Alisha. I'll handle that one. If you step back, SPINRAZA is nearly 10 years past the arrival of the first SMA therapy, and what you're probably observing is that SPINRAZA continues to define the efficacy standard in this area. And if you consider how SPINRAZA HD came to exist at all, it goes back several years, when a lot of patients approached Biogen and told us they simply wanted more. They wanted more; they felt an even larger dose was something they could take. Biogen then, clearly, moved forward and created this new formulation. So today we have high dose; and since launching, what we're witnessing is essentially demand and urgency that this patient community is really fueling. Actually, on metrics: in its first 13 weeks, SPINRAZA high dose has surpassed the original SPINRAZA launch on both start forms and grads, and we keep growing week after week. So looking at Q2 revenue, sites place orders for high dose so each patient is ready for their next dose. Given how the product is dosed, you must wait 1 quarter or 2, based on when the patient last received SPINRAZA. Feedback from patients who've gotten the product thus far has been quite positive, and from physicians too; the teams are actively backing payer approvals, account P&T reviews, and patient transitions. In this initial bolus of launch demand, most patients are moving from spin 12 megs over to high dose. That said, we also have a number of patients who are either new to SPINRAZA — especially babies, since we hadn't dosed a baby in years — so babies are now being dosed; and we've also had a number of switchbacks from RD. So for this year, what you should expect is that bolus of transitions carrying into the start of next year, while our major focus for 2027 will be new starts and switchback. One of the advantages you have that we didn't anticipate would be such a positive in the market. With the 12 mg spin, you get 4 loading doses at the high dose, whereas there are just 2. And we do see patients who'd rather take 2 as their loading doses instead of 4, and that's also where you're noticing a portion of the switchbacks along with new patient starts.

Executive

executive
#10

Yeah, and actually the U.S. is one of the last markets where Axeon typically gets launched. So in Japan, where we launched sooner, like in Europe, that's where we're actually seeing — especially in Germany — a reversal of that trend of switching to oral therapy, with some patients now trending back. I think it's still early days; and like Alisha said, it's mostly the first people moving from the lower dose to the high dose; but again, like Alisha said, in all markets, and I go talk to physicians around the world when I'm visiting our affiliates, at the end of the day, it's really in these devastating diseases efficacy that really matters, and there is an enhanced opportunity here for that.

Umer Raffat

analyst
#11

I'd like to revisit what you're expecting before the lupus data come out this fall. More precisely, Benlysta has shown a separation on SRI in the mid-teens, and AstraZeneca's Safanella has come in somewhere in the 20s. Based on everything your team has learned, what gap versus placebo would you regard as strongly clinically meaningful and clearly differentiated from what's already available on the market? And Priya, would you remind us which dose of your BTK inhibitor is being carried forward? I'm considering the liver effects, but I'd really like to hear the dose.

Priya Singhal

executive
#12

Priya here, and I'll handle that. To begin with, our TOPAZ trial has us very enthusiastic. That covers TOPAS 1 and 2. Results from both should arrive in Q4 of this year; those are our SLE studies. So perhaps, to pull back a bit, I'd note that we incorporated every lesson from earlier studies to make sure these were designed correctly; specifically, we directed attention at the elevated placebo responses observed previously. Within our studies, there were provisions restricting standard-of-care use — meaning NSAs, corticosteroid tapers, and how responder and nonresponder data get handled; beyond that, we also moved forward by acknowledging this disease is heterogeneous. So in what way do we manage heterogeneity across patients and participants? We attempted to shape our inclusion/exclusion criteria so they align very closely with the Phase II LILAC proof of concept; as for our expectations, I'd say our confidence in the trial design, the sites chosen, and patient selection remains strong, all aimed at achieving a robust response. How we actually fare in the study will become clear, and we'll await the results. I won't engage in speculation. SRI4 serves as our primary endpoint; even so, a key secondary endpoint exists in <<inaudible>>, plus we have several patient-reported outcomes. Thus we'll be examining the data in its totality, <<inaudible>> included, and 52-week data will be presented at EADV this fall, so our confidence in that data set also holds. Turning now to your second point about the BTK inhibitor: doses have not been disclosed by us, I won't provide additional detail, and we're evaluating possible next steps for it.

Chris Viehbacher

executive
#13

Alicia, is there anything you'd like to add regarding the market research? Since I believe — this is 1 of those situations where success won't be marked by any single factor. You have steroid sparing. A complaint we hear repeatedly from patients involves fatigue, but incorporating fatigue as an endpoint in clinical trials isn't really that straightforward; real-world evidence will therefore matter, though perhaps you could offer a few comments about what commercial success is going to require.

Alisha Alaimo

executive
#14

Absolutely, Chris. Thanks for that. Umer, it's great to hear your voice. To begin with, we've brought on board a number of senior leaders who have lupus experience, a full medical team with lupus experience, and multiple marketers with lupus experience. And I'd say the insights we've gained from them likely exceed what you'd get from third-party market research. We often discuss things such as SRI-4 and endpoints, but when you actually observe the interactions between a physician and a patient, what we're discovering in this market is a massive gap in what they anticipate from treatment. Physicians want to gauge a patient's experience solely based on lab results, while patients come in and say the 3 things really troubling me are fatigue, brain fog, and joint pain. And I genuinely believe in this market, when you look at CLE, where fewer than 5% of CLE patients are on advanced therapy. And also — since there's no approved therapy, I think the CLE patient numbers are undercounted. I know we've reported 75,000. I believe that figure is far lower than the real number out there. Secondly, you're seeing patients get lost in the system, being shuffled from derm to rheumatology and rheumatology to derm, where nobody truly knows how to treat them. And then with the treatments currently on market, there are shortcomings. One doesn't act very quickly or very effectively, and another has an infection safety concern. So when you talk to these physicians, they're really seeking a treatment that can work much faster and can work in both CLE and SLE. So I think there's a very long runway for this therapeutic area. And since there's such a huge unmet need in these patients, they are known; we can track them in the system because they are — most of them are diagnosed; we know which physicians diagnosed them and who they see. I think that even though there's a lot of work to do, I find this to be a very good therapeutic area to enter.

Marc Goodman

analyst
#15

Yeah. Could you share a bit more detail about SYFOVRI and what's actually going on beneath the surface — for instance, new patient starts, or how long patients are staying on it? We get that injections rose 13%. But I'm just trying to grasp what's happening there and what sort of growth we ought to anticipate going forward? .

Alisha Alaimo

executive
#16

Thanks for asking. A great deal has been happening with SYFOVRI ever since we were able to bring them into the organization. First off, I want to say I'm extremely impressed and extremely thankful for the caliber of talent and expertise that came over from the Sipo routine. When SYFOVRI and EMPAVELI first came into the company, my sense is that both had fairly similar approaches to their launches. Over these past 7 years and 7 launches, though, what we've really come to understand is that we tailor each launch individually. We build them fresh, starting from nothing. Our launches are informed and well-executed, and they aren't based on a template. So we've been able to work alongside the SYFOVRI team across the whole organization, figuring out what's genuinely driving sales, where we might move capital around, and how to bring the Biogen machine in to help build on some of that momentum. I'm really encouraged, because this was the strongest quarter since SIFOVRI actually launched. June also came in as the strongest month the brand has ever had. So what we're seeing is growth that's high quality across several dimensions. First, I'd point out that our free drug has been reduced by 50%; we went through the free drug programs and looked at where we could add some guardrails so that only patients who truly require free drug access end up getting it; that figure has dropped by half, and that's contributed to the momentum. Second, when you consider how this brand started out in terms of how HCPs felt about slowing GA progression, and compare that to where doctors are now, the SYFOVRI team has accomplished something truly impressive in changing those perceptions. And since sentiment has risen so dramatically, that's the reason you're seeing additional prescribers join in. That's also the reason a much larger number of patients are getting on board. They achieved growth in both the count of patients and the number of physicians writing prescriptions; and one factor I'd point to as a tailwind behind that was the 5-year long-term data they've been presenting, which amounts to a great deal of education regarding how GA progresses. Looking forward, among retina specialists, just half are currently providing treatment, and a mere 20% of those patients have received a diagnosis. Because of that, the team has been examining a few key areas. First, there's the direct-to-consumer approach. We decided to discontinue multiple programs and redirect that funding into a fresh commercial push. It's possible the SYFOVRI team and its leadership believed their DTC effort came somewhat early, since we now view the market as prepared; we intend to introduce a DTC campaign that we anticipate will deliver strong results. Second, the prefilled syringe — we're also very excited about that launch. The prefilled syringe will genuinely help physicians with their workflow. Our view is it will speed things up considerably for them, boost efficiency, and they likely can deliver more injections into the eyes while saving roughly 15 minutes on those injections; so that's great as well; but even more significantly, on an earlier call, I believe I told you that when we were examining SYFOVRI, one finding from our diligence was that a substantial discount existed, with many patients discounting after a year. Well, with the team now in place and after a real look at the data, we've observed that in fact discounting occurs following the first injection. That explains where that big lump comes from, though you won't actually see it show up in the figures until a full year has passed and that 50% decline becomes visible. Given everything we've learned across all our brands, where rebate issues cropped up following either the initial shot or the first intravenous infusion, we now have a clear playbook for dealing with it. So the team is also being rallied around the work of educating those patients and their physicians on why a rebate isn't needed after that first injection, and on what kind of instruction belongs in the doctor's office. As things stand right now, we see HCP growth heading in a favorable direction, and we expect to keep up that momentum. And after that, our focus will shift to educating patients and activating them through DTC.

Salveen Richter

analyst
#17

I just want to go back to BIIB091, your BTK inhibitor. Can you tell us why you think this one would stand apart from the assets further along in development, and what your view is on the safety profile based on what has been observed?

Priya Singhal

executive
#18

Thanks, Salveen. Priya here. To give some context, several years back we moved BIIB091, a noncovalent peripheral BTK inhibitor, into a Phase II study in RRMS. That study has now wrapped up. What we observe is potentially strong efficacy in RRMS; however, as I said during my remarks, we are weighing what the right next move should be, since we view RRMS as a highly crowded and competitive space. At the same time, we are considering the external shifts we have witnessed across the BTK field; so we will share more later about how we expect this asset to move forward. No decision has been made yet to move it specifically into an indication. So that step has not happened. The data is still under evaluation. On the whole, we believe it could do very well in RRMS, yet I think this is one more key illustration of how we set priorities for assets in our portfolio, where we examine the scientific data, but we combine that with the value and the opportunity in terms of the full picture and really how capital gets allocated. So here is a case where we are pausing; we are reviewing the data, and we will determine how and when and whether we would move it forward past where it stands today. I hope that answers your question.

Michael Yee

analyst
#19

Thank you. What we're really asking about is litefilimab in CLE. Given that there may be less variability among those patients—you've already discussed certain dangers in SLE, like heterogeneity and placebo response rates—do you think CLE has a greater chance of success? So could you share your perspective on CLE compared with SLE, and maybe discuss some of the findings you'll be presenting at EADV that might increase confidence, since I believe more data is coming?

Priya Singhal

executive
#20

Taking a step back, honestly I don't perceive any difference when it comes to the likelihood of success between SLE and CLE, and I stay confident in the results from our LILAC Phase II study, which we consider was a strong proof-of-concept trial. It mattered because we studied the SLE population. That said, it was enriched for the group where, according to its mechanism of action, we expect litefilumab to deliver its greatest effects. So our SLE study was designed to focus quite narrowly on individuals with skin and joint manifestations. That's why I continue to feel confident about the way this trial has been constructed and about its chances of success. In the same way, for CLE, I'm also confident, thanks to the emphasis on skin and the results we've produced up to now. It's simply the case that with SLE, because the indication is broad and the disease is sadly very common, we have 2 Phase III studies—and for CLA, we have a Phase II plus Phase III study, which was a seamless design, the AMICUS trial. So you might recall that we do have a chance to present Phase II results. It isn't that we feel more or less confident, which is why we're sharing them. We can examine the Phase II findings on their own without interfering with the Phase III component, and we're merely carrying that data forward and taking it to EADV. Earlier this year we already presented the randomized controlled portion of Ametis Phase II; so at this point we're presenting the 52-week results, which we hope will tell us more regarding how long responses last. But no, I'd say we stay confident across all 3 trials. And as was noted, we believe this condition is truly significantly undertreated. Only a small number of biologics have succeeded; and they haven't truly gained traction in the market, and in our view that actually ties back to their treatment response; and we believe that with the correct mechanism of action, we genuinely have a very—we would be—we could address a very substantial unmet need in this space.

David Amsellem

analyst
#21

Regarding Impavly, I see you're starting a Phase II trial in FSGS. I'm curious, in a broad sense, how extensive a development effort do you plan to mount for this molecule — given that it inhibits complement C3 — and what other indications might you be considering past FSGS? Then, second, could you speak to your anti-CD40, which is ready for Phase I? Perhaps you could address how its mechanism differs from that of the CD40 ligand antagonist, as with alibabat, where Amgen is conducting a Phase III program in sovereigns.

Priya Singhal

executive
#22

Let me begin with that. We continue to feel enthusiastic about having brought in EmpoBelly, and naturally its nephrology uses, plus the proxy and hemoglobin urea, stay quite significant commercially. Yet ever since — when we brought this in, our legacy Apellis group had already been developing many indications, and after reviewing them, two notable nephrology studies were under consideration. The first was delayed graft function, which we have based, and we would not be moving that one forward. The FSGS, though, we think, stays a genuinely important indication. Why? Because we see it as having high unmet need; it offers clarity around the primary endpoint and the regulatory path, along with EmpoBelly's capacity to genuinely target the C3, C3B cleavage pathway and thus affect the auto antibodies. We also possess real-world data, as well as muting models in which we've observed elevated C3 levels; so we feel this truly is a science forward approach. And we're being quite prudent; we're advancing this as a Phase II proof of concept, and data could arrive quite soon after the trial begins. We have also already sought — I believe our Ampobelly legacy team has already sought feedback from the FDA. So this still arrives with a genuinely attractive package, which we think is worth pursuing. That's our current position; we'll be examining broadly where complement, specifically C3, plays a major part in disease; yet the other aspect, as I noted in that other example a moment ago, is truly the value proposition. So we constantly assess the addressable market. Take FSGS, for instance: we know roughly 27,000 patients exist in the U.S. We know there are 4 types. We'll be conducting a very clear and decision enabling trial to genuinely inform our next steps. Now, turning to your second question regarding the anti-CD40, we stay enthusiastic about the pathway — we consider it differentiated and it might be something we advance also in autoimmune disease. We haven't disclosed that yet, but we'll be communicating more once the timing is appropriate.

Alexandria Hammond

analyst
#23

It's been several weeks now since the complete Celia dataset was posted or presented by you at AAIC. Given that you've had time to absorb how the medical and regulatory community responded, what sort of feedback has come your way — and has any of it caused you to rethink anything about the Phase III trial design, especially regarding the possibility of early combination with Abeta antibodies?

Executive

executive
#24

Yeah, that one's mine to answer; like I mentioned during my remarks, DerNurson genuinely belongs to Biogen's longer-term narrative. The Phase II, in truth, was an exploratory study. Its primary goal was essentially determining whether lowering tile translates into cognitive improvement. Until this point, Tau amounted to a theory; a beloved theory, sure, yet still only a theory. Nobody before this had produced any data on it. As for the business choice to actually proceed with it, Priya had already — once we received the data range, an independent biostatistician reviewed it; an outside KME examined it prior to our announcement, multiple advisory groups were held; we had the AIC. Among the strongest pieces of feedback: the signal is genuine. Chance isn't responsible here. Plenty of folks arrived at that point through heavy overanalysis regarding the dosing question. Numerous hypotheses exist. One thing stands out — tau clearly matters for neurotransmission. So although an excess isn't beneficial, perhaps an insufficient amount isn't either; we simply lack that knowledge. That's what being in breakthrough involves. It's quite thrilling, yet it's likewise among the reasons our decision was not to build the company around this sort of product. This falls into the high risk, high reward category. We're conducting substantial investigation and holding discussions with the neurology community; and clearly, consultation with the FDA will happen. Long-term extension data are also on the way, and we'll make them available. Still, this represents a long-term investment; it will be — our confidence in the signal is solid. It might become an exciting option, but Phase III remains necessary, and it won't influence Biogen's growth throughout the remainder of this decade; so that's everything we wish to share regarding dearnersing right now.

Brian Abrahams

analyst
#25

Nice quarter. Regarding subcu for induction, I'm just wondering how initial demand or interest has appeared on the ground compared with what you expected? Then, your current thinking on access dynamics and possible timelines in that area. .

Alisha Alaimo

executive
#26

Thanks. I'll handle that. As you're aware, we got approval earlier this month for LEQEMBI IQLIK induction, and by the end of August it will be on the market. So here's what we've done: our field teams have been trained; we're educating the HCPs and informing them that availability should come next month; thus, some demand has already appeared. Naturally, it isn't being filled yet, but those requests are placed into a queue. And so we've had — as of yesterday, scripts have already been written by several physicians. And so we aren't truly including that in our expectations yet, until the product is genuinely readily accessible for the market. So we're watching that closely. Now, as you're also aware, Eisai is attempting to make access quite easy for this and as simple as they can; and they're the ones dealing with the payers regarding Part D access. In a few months, we'll find out once more what kind of access will be available when next year starts. That said, should certain Part D plans choose not to contract, there's still another path for LEQEMBI IQLIK — the same one they've relied on with IQLIK maintenance — namely medical exceptions. When we look at the data on the medical exception rate for this product, it comes out quite high, above what we see in most other therapeutic areas. So even in cases where a physician goes ahead and files one, the approval rate on granting is high, which means the patient ends up receiving the product. We still don't know what the situation will look like when coverage changes on January 1 of next year. Keep in mind, even with a Part D plan in place, someone has to complete a prior authorization. That means physicians are either completing a prior auth or completing a medical exception form for the product. Additionally, our recently conducted market research leads us to expect that IQLIK will transform this market. It'll also add to growth down the road once it's up and running. Just remember, most of the LEQEMBI protocols out there were written with IV in mind, so many IDNs, hospitals, and systems are beginning to revise them so that IQLIK gets included in their workflow as well. And as Chris noted before, if you look at drop-off rates — and there are drop-offs at various stages along a patient's journey — one stands out in particular: when a patient finally reaches a physician who supports AAT and is ready to write a prescription, among the biggest drop-offs is that patients simply don't want to receive IV, and that's true regardless of LEQEMBI or <<inaudible>>. Our market research also gives us confidence that those individuals would choose to receive treatment subcutaneously. Consequently, a substantial share of people discontinue precisely because of that issue. Thus, in our view, this factor should likewise contribute to speeding up expansion of the market.

Paul Matteis

analyst
#27

At this moment, in what ways are you folks considering the brain channel space? Also, when you consider how heavily you're putting money into establishing this Alzheimer's market, does it seem to you that Biogen must possess a brain channel in order to seize what the sales potential for A beta will be? And if that's the case, what would be the optimal route to achieve it?

Priya Singhal

executive
#28

For us, it's a hugely significant domain and has been for some time, taking in whatever data readouts we've recently had. So that's all I'm able to say; internally, we are doing work. We're looking outside the company as well, and regarding shuttle delivery, we've been engaging in that work quite intensively here. Thus, our interest in reaching tissue delivery modalities stays very strong; and my sense is we'd consider that spanning multiple targets. That's what I can convey, though for us it ranks as a top priority.

Executive

executive
#29

Absolutely. Over the longer horizon, Alzheimer's will definitely be one of the central pillars of Biogen's portfolio, especially given that there's now a strong likelihood Derinersen eventually reaches the market. Obviously, the Phase III program still has to be completed. That said, I think when you consider — what truly matters in this market, and you've spoken with physicians who actually treat patients, is genuinely improving cognition. That's precisely why we've chosen to move forward with deranursen. At this point, having a portfolio of products probably makes sense. We're even having discussions internally — no decisions have been made yet — about whether you'd combine an A beta with an anti-tau, for instance. There's a question of whether, after administering, say, 3 or 4 injections of anti-tau, you might not even need it anymore, or perhaps you'd need just an <<inaudible>> to actually stop the tau from returning. All of these possibilities are things we're currently evaluating. Something like this would certainly impact the business over the coming decade. But I think if we're going to play in Alzheimer's, we're definitely aiming to have a portfolio. And clearly, brain shuttles would represent the next generation of products to pursue. As Priya mentioned, we've been working on that for several years now.

Evan Seigerman

analyst
#30

Chris, I believe you said felzartamab and AMR might represent a $2 billion opportunity. That figure isn't really captured in Biogen's present valuation. What do you think we investors would need to witness before we're persuaded of it? And what might you be able to show us once that data arrives next year?

Chris Viehbacher

executive
#31

Thanks, Evan. Something we noticed while conducting diligence on the Pallas was that hardly any value had been tied to EMPAVELI; I believe there's a habit of concentrating heavily on a company's lead products. For certain of these programs, where no treatment exists, there are likewise no analogs. So what we observe, and what we've heard from many analysts and experts, is that a placeholder value tends to get assigned. Then people prefer to hold off until they see the data. But 1,000 patients. And if you applied even the Otsuka price for iGame 350,000, you'd arrive at a market somewhere between $3 billion and $4 billion. And bear in mind that the Phase II data demonstrated an 80% resolution of AMR in an open label in a small study, and obviously we have to repeat that in a Phase II. Yet no product is approved for AMR today. So — and for patients the option is either treatment with felzartamab or possibly a second kidney transplant. I mean, I was in I was in Brazil recently and visited the hospital where they perform more kidney transplants than anywhere else in the world; they estimate that somewhere between 10% and 20% of people on the kidney transplant list are people who have already had a kidney transplant. So there's a huge unmet need; this is a product that really seems to work; so we have very high hopes for this product.

Terence Flynn

analyst
#32

Perhaps I could ask something that builds on what was just discussed. This one is likely directed at Chris or Priya. Regarding the TRANSCEND trial, could you refresh our memory about the statistical power for the primary endpoint, and what the FDA needs in order to grant approval in the late AMR indication? After that, how ought we to consider the broader read-through from TRANSCEND when it comes to microvascular inflammation?

Priya Singhal

executive
#33

Sure. Let me take that first part. What I'd say is that we have not made any public statement regarding the powering. Our view is that the design is quite robust, with power that genuinely lets us feel confident about the result. So our confidence in how the trial was designed continues. As you're aware, this study — the TRANSCEND trial — lasts 6 months and is placebo controlled. It relies on biopsy as the endpoint, and that matters a great deal. Following that, patients transition to maintenance across the subsequent months; I'd say both durability and that 6-month time point carry weight. We managed to — and I think this is yet another encouraging indicator — we managed to speed up the trial. As a result, we now anticipate data during the first half of 2027. On the whole, I'd say our excitement continues. Turning to MVI, it clearly represents a newer diagnostic criterion, coming by way of the BAMS criteria. That matters since these patients test negative for donor-specific antibodies, yet this group is a highly significant one. Together with our high Bio team — genuine specialists in this field — what we chose to do was get the MVI trial, known as the transpire trial, started without delay. That study is therefore already running. Data will consequently come out of it as well; and our belief is that indeed, the way fazatemab works — targeting plasma cells and the anti-CD38 action — will make a difference in MVI and in AMR alike. Within the U.S., MVI on its own covers a substantial group, roughly 6,000 patients. So this stays a significant secondary yet extremely significant piece of the unmet need; we therefore regard it as a truly major opportunity, and our confidence holds that <<inaudible>> has a strong likelihood here of delivering the data we seek.

Tim Power

executive
#34

Appreciate all of you being here with us right now. Should any follow-up questions come up, you're aware of how to reach us. Be well.

Operator

operator
#35

Thanks so much, everyone, that brings today's call to a close; we appreciate you joining us. At this point, you're free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.